FDA authorizes COVID-19 breathalyzer test
April 15, 2022—The FDA issued an emergency use authorization to InspectIR Systems for its InspectIR COVID-19 Breathalyzer test.
Webinars and Sponsored Roundtables — Register Now
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
BioMérieux acquires Specific Diagnostics
April 12, 2022—BioMérieux has entered into an agreement to acquire Specific Diagnostics, a privately held U.S.-based company that developed a rapid antimicrobial susceptibility test system.
Tempus unveils Edge pathology-driven AI platform
April 1, 2022—Tempus has announced plans to launch Edge, a platform that will enable pathology practices to access the company’s digital pathology AI models, during the second half of this year.
Accelerate Diagnostics launches Arc module, BC kit
March 28, 2022—Accelerate Diagnostics launched the Accelerate Arc system for rapid and accurate microbial identification of positive blood cultures.
BioMérieux gets FDA 510(k) clearance for Vitek MS Prime
March 18, 2022—BioMérieux announced the Vitek MS Prime, its new MALDI-TOF mass spectrometry identification system, received FDA 510(k) clearance.
CE-marked Nova Max Pro creatinine/eGFR meter launched
March 11, 2022—Nova Biomedical launched the CE-marked Nova Max Pro creatinine/eGFR meter system in the EU market.
Opdivo + chemo approved as neoadjuvant treatment for NSCLC
March 9, 2022—The FDA has approved Bristol Myers Squibb’s Opdivo (nivolumab) in combination with platinum-doublet chemotherapy for adult patients with resectable non-small cell lung cancer in the neoadjuvant setting.
Paragon Genomics unveils Emerging Variant Add-on V2
Feb. 24, 2022—Paragon Genomics announced the release of its Emerging Variant Add-on V2.
Tribun Health nabs KLAS award for digital pathology
Feb. 22, 2022—Tribun Health announced it won a 2022 “Best in KLAS” award for digital pathology in Europe.
FDA clears Streck MDx-Chex for BCID2
Jan. 31, 2022—Streck’s MDx-Chex for BCID2, a quality control designed to meet the standards for verifying the performance of the BioFire BCID2 panel assay for sepsis, has been granted FDA clearance for in vitro diagnostics use.